CLEC4E

Across TCGA pan-cancer cohorts, CLEC4E Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLEC4E data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CLEC4E Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLEC4E expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, ESCA, and SKCM are the cancer types where CLEC4E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →
ESCA	DFS	Median	II,III,IV	0.149	0.522	.047	3	view →
SKCM	DFS	Median	II,III,IV	0.894	0.669	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLEC4E–LIHC (DFS)

Open the LIHC breakdown →